Bicyclic Peptide Treats Blindness

  • Author: Meghan Campbell
  • Published: 09 April 2018
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
  • Source / Publisher: Journal of Medicinal Chemistry/ACS Publications
  • Associated Societies: American Chemical Society (ACS), USA
thumbnail image: Bicyclic Peptide Treats Blindness

Blindness or vision loss associated with diabetes is expected to rise by around 30 % in the next ten years. The primary cause of this type of blindness is diabetic macular edema, due to blood vessels in the eye that leak fluid into the retina. Targeting one of the factors involved in regulating vessel permeability, plasma kallikrein (PKal), would represent a new method for treating macular edema.

Jean H. M. Feyen and a group of scientists from Bicycle Therapeutics, Cambridge, UK, and Thrombogenics, Leuven, Belgium, have screened a phage-display library to find potent and specific peptide inhibitors of PKal. By identifying bicyclic peptides that bind to the target, potency can be increased because cyclization stabilizes the formation of the epitope. The team subsequently performed substitutions at key positions of the peptides to increase the stability of the peptides in vivo.

The two most effective peptides identified were found to be highly specific for PKal, showing almost no cross-reactivity with other serine proteases. Strangely, the peptides did not significantly increase the coagulation time of blood, but this could be because PKal is not the primary trigger for coagulation to occur.

The peptides were shown to be highly stable in vitreous fluid and initial experiments in rats and mice indicated that the effects on edema were at least equivalent to previously approved drugs. While these studies remain preliminary, a new method for treating diabetic retinopathy could affect millions of people struggling with vision loss.


 

Article Views: 924

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH